14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
CDIO vs CING: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 17, 2026, Cingulate Inc. (CING) captures the overall head-to-head institutional edge over Cardio Diagnostics Holdings Inc. (CDIO) on higher Unified Composite conviction (44.8/100 HOLD vs. 39.4/100 SELL) after splitting the core matrix 4–3 (led by Options & Positioning), while CDIO wins 3–1 across the 6-pillar growth and valuation breakdown. CDIO trades at $1.75 (N/M Forward P/E, -42649.8% operating margin) versus CING at $4.76 (N/M Forward P/E, 0.0% operating margin).
Growth vs. Quality Trade-Off: CING earns the overall head-to-head edge with a stronger Unified Composite Score (44.8/100 HOLD vs. CDIO 39.4/100 SELL) and 1.13β · 117% Vol risk profile, whereas CDIO leads top-line expansion (+25.7% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: CDIO trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 47.9); meanwhile CING is in a Breakdown options structure phase (RSI 51.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CDIO vs CING. Trailing 12-month operating profitability (CDIO -42649.8% vs CING 0.0%) and valuation multiples (CDIO N/M vs CING N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $62.5M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ CDIO vs CING Key Questions & Quantitative Answers
As of Nov 17, 2026, Cingulate Inc. (CING) captures the overall head-to-head institutional edge over Cardio Diagnostics Holdings Inc. (CDIO) on higher Unified Composite conviction (44.8/100 HOLD vs. 39.4/100 SELL) after splitting the core matrix 4–3 (led by Options & Positioning), while CDIO wins 3–1 across the 6-pillar growth and valuation breakdown. CDIO trades at $1.75 (N/M Forward P/E, -42649.8% operating margin) versus CING at $4.76 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: CING earns the overall head-to-head edge with a stronger Unified Composite Score (44.8/100 HOLD vs. CDIO 39.4/100 SELL) and 1.13β · 117% Vol risk profile, whereas CDIO leads top-line expansion (+25.7% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: CDIO trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 47.9); meanwhile CING is in a Breakdown options structure phase (RSI 51.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
CDIO leads the Growth & Scale pillar: CDIO posts +25.7% YoY revenue growth and +0.0% YoY earnings growth on $15,185 TTM revenue (100.0% gross margin, -42649.8% operating margin), compared with CING at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, CDIO generates $15,185 in USD-normalized revenue versus N/A for CING. In operating R&D and SG&A reinvestment, CDIO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CING.
CDIO and CING trade at balanced relative valuation multiples. CDIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas CING trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CDIO (-93.5% ROE) versus CING (-198.7% ROE) capital efficiency.
In options market volatility and institutional positioning, CDIO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.44β · 56% Vol realized risk). By comparison, CING carries 111.1% implied volatility (16th %ile, Compressed (<25th %ile)), a 0.07x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.13β · 117% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.